CLAIMS:

1. A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.

2. A composition comprising an effective amount of a polysulfated polysaccharide including salts thereof, and a pharmaceutically acceptable carrier for the treatment of bone marrow edema in a mammal.

3. Use of a polysulfated polysaccharide including salts thereof, in the manufacture of a medicament for the treatment of bone marrow edema.

4. A method according to claim 1, a composition according to claim 2 or a use according to claim 3 wherein the polysulfated polysaccharide is selected from the group consisting of high molecular weight heparin, low molecular weight heparins, the heparan sulfates, pentosan polysulfate, chondroitin polysulfate, chitosan polysulfate, dermatan polysulfate sulodexide, dextran sulfate, polysulfated inulin, sulfated lactobionic acid amide, sulfated bis-aldonic acid amide, sucrose octasulfate, fucoidan-1, fucoidan-2, sulfated beta-cyclodextrin, sulfated gamma-cyclodextrin and small sulfated compounds including, but are not limited to, inositol hexasulfate.

5. The method, the composition or the use according to claim 4 wherein the polysulfated polysaccharide is selected from the group consisting of high molecular weight heparin, low molecular weight heparins, pentosan polysulfate, chondroitin polysulfate and chitosan polysulfate.

6. The method, the composition or the use according to claim 5 wherein the polysulfated polysaccharide is selected from the group consisting of pentosan polysulfate, the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), and the calcium salt of pentosan polysulfate (CaPPS).

7. The method, the composition or the use according to claim 6 wherein the polysulfated polysaccharide is sodium pentosan polysulfate.

8. The method, the composition or the use according to any one of claims 1 to 7 wherein treatment is by administering an injection by the intra-muscular (IM) or sub-cutaneous (SC) routes, intra-venously (IV), intra-articularly (IA), peri-articularly, topically, via suppositories or orally.

9. The method, the composition or the use according to claim 8 wherein the treatment is by administering an injection.

10. The method, the composition or the use according to any one of claims 1 to 9 wherein the effective amount is about 1 to 2 mg/kg of the mammal per dose.

11. The method, the composition or the use according to claim 10 wherein administration to a human is by dosing in a treatment regimen once daily or thrice weekly.

12. The method, the composition or the use according to claim 11 wherein the total dose of polysulfated polysaccharide administered in the treatment regimen is about 200-2000 mg.

CLAIMS:

1. Use of a polysulfated polysaccharide selected from the group consisting of high molecular weight heparin, low molecular weight heparins, pentosan polysulfate, chondroitin polysulfate, chitosan polysulfate and heparan sulfates including salts thereof, in the manufacture of a medicament for the treatment of bone marrow edema.

2. The use according to claim 1 wherein the polysulfated polysaccharide is selected from the group consisting of high molecular weight heparin, low molecular weight heparins, pentosan polysulfate and heparan sulfates.

3. The use according to claim 2 wherein the polysulfated polysaccharide is selected from the group consisting of pentosan polysulfate, the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), and the calcium salt of pentosan polysulfate (CaPPS).

4. The use according to claim 3 wherein the polysulfated polysaccharide is sodium pentosan polysulfate.

5. The use according to any one of claims 1 to 4 wherein the treatment is by administering an injection by the intra-muscular (IM) or sub-cutaneous (SC) routes, intra-venously (IV), intra-articularly (IA), peri-articularly, topically, via suppositories or orally.

6. The use according to claim 5 wherein the treatment is by administering an injection.

7. The use according to any one of claims 1 to 6 wherein the effective amount is about 1 to 2 mg/kg of the mammal per dose.

8. The use according to claim 7 wherein administration to a human is by dosing in a treatment regimen once daily or thrice weekly.

9. The use according to claim 8 wherein the total dose of polysulfated polysaccharide administered in the treatment regimen is about 200-2000 mg.